SCHEMBL4458514

SCHEMBL4458514

CN1CCN(Cc2ccc(-c3cc4c(N5CCN(C)CC5)ncnc4[nH]3)cc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 6/20 0.72
PRMT5 O14744 3/20 0.66
KIT P10721 5/20 0.56
KDR P35968 2/20 0.54
HRH4 Q9H3N8 2/20 0.54
EGFR P00533 2/20 0.53
STK10 O94804 1/20 0.53
MAP4K4 O95819 1/20 0.53
ABL1 P00519 1/20 0.53
ERBB2 P04626 1/20 0.53
YES1 P07947 1/20 0.53
RET P07949 1/20 0.53
PDGFRB P09619 1/20 0.53
BCR P11274 1/20 0.53
FLT1 P17948 1/20 0.53
ERBB3 P21860 1/20 0.53
WEE1 P30291 1/20 0.53
ABL2 P42684 1/20 0.53
NEK3 P51956 1/20 0.53
LIMK1 P53667 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5100203 0.87 CSF1R (0.58) CSF1RPRMT5KDREGFRSTK10
SCHEMBL4067576 0.85 KDR (0.60) CSF1RPRMT5KDREGFRSTK10
SCHEMBL15515306 0.85 KIT (0.70) CSF1RKIT
SCHEMBL4064609 0.84 CSF1R (0.60) CSF1RPRMT5KDREGFRSTK10
Ammonia Solution, Strong SCHEMBL4467562 0.84 KDR (0.56) CSF1RPRMT5KDREGFRSTK10
SCHEMBL4069403 0.83 KDR (0.67) CSF1RKDREGFRSTK10MAP4K4
SCHEMBL4065308 0.82 CSF1R (0.62) CSF1RKDREGFRSTK10MAP4K4
SCHEMBL4066503 0.82 KDR (0.58) CSF1RPRMT5KDREGFRSTK10
SCHEMBL4066506 0.82 CSF1R (0.53) CSF1RPRMT5KDREGFRSTK10
SCHEMBL24596893 0.81 CDK9 (0.57) CSF1RKDREGFRSTK10MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625894-B2 Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors NOVARTIS AG (CH) 2009-12-01 US claimed
US-20070135460-A1 7H-pyrrolopyrimidine derivatives CARAVATTI GIORGIO 2007-06-14 US claimed
CN-1922184-A 7H-pyrrolopyrimidine derivatives NOVARTIS AG (CH) 2007-02-28 CN claimed
EP-1718651-A2 7H-PYRROLOPYRIMIDINE DERIVATIVES Novartis AG (CH) 2006-11-08 EP claimed
WO-2005077951-A2 7H-PYRROLOPYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2005-08-25 WO claimed
US-7625894-B2 Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors NOVARTIS AG (CH) 2009-12-01 US disclosed
US-20070135460-A1 7H-pyrrolopyrimidine derivatives CARAVATTI GIORGIO 2007-06-14 US disclosed
CN-1922184-A 7H-pyrrolopyrimidine derivatives NOVARTIS AG (CH) 2007-02-28 CN disclosed
EP-1718651-A2 7H-PYRROLOPYRIMIDINE DERIVATIVES Novartis AG (CH) 2006-11-08 EP disclosed
WO-2005077951-A2 7H-PYRROLOPYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135460-A1 7H-pyrrolopyrimidine derivatives DPYD, TYMP, DHPS CSF1R 3432/4885PRMT5 531/4885KIT 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.